Mission Statement, Vision, & Core Values of Alaunos Therapeutics, Inc. (TCRT)

What drives a company like Alaunos Therapeutics, Inc. (TCRT)? Is it purely about the bottom line, or is there a deeper purpose guiding their actions? Understanding a company's mission, vision, and core values offers invaluable insight into its strategic direction and corporate culture, especially when they reported a net loss of $4.68 million USD for the full year ended December 31, 2024.

Delving into these guiding principles can reveal what truly motivates Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company, and how they aim to navigate the complexities of the biopharmaceutical industry, particularly as they explore strategic alternatives. Are you curious to learn more about the values that underpin their pursuit of innovative cancer treatments and their impact on the future of healthcare?

Alaunos Therapeutics, Inc. (TCRT) An Overview of

Alaunos Therapeutics, Inc. (TCRT), is a clinical-stage oncology-focused company. Alaunos is developing T-cell receptor (TCR) therapies targeting solid tumors. These therapies leverage the body's immune system to fight cancer. The company's lead TCR T-cell therapy candidate is TCR-T Library™, designed to target multiple shared neoantigens. Alaunos is also working on developing additional TCR T-cell therapies and has a pipeline of preclinical programs.

As of April 2025, Alaunos Therapeutics continues to focus on advancing its TCR-T Library™ and other therapies through clinical trials. While specific, real-time sales figures for April 2025 are not available, the company's financial performance is typically detailed in its quarterly and annual reports. For the fiscal year 2024, Alaunos reported financials reflecting its ongoing research and development activities. These reports provide insights into the company’s cash reserves, expenditures, and progress in its clinical programs.

To delve deeper into Alaunos Therapeutics, Inc., including its history, mission, and ownership structure, explore: Alaunos Therapeutics, Inc. (TCRT): History, Ownership, Mission, How It Works & Makes Money

To assess Alaunos Therapeutics' financial performance, it's essential to review their latest financial reports. As a clinical-stage company, a significant portion of their expenses is related to research and development. Investors and stakeholders closely monitor these expenditures, cash runway, and any revenue generated through collaborations or licensing agreements.

Alaunos Therapeutics aims to be a leader in the development of TCR T-cell therapies for solid tumors. The company's approach involves targeting shared neoantigens, which are present in multiple cancer types, potentially allowing for broader application of their therapies. The success of Alaunos depends on the outcomes of its clinical trials and its ability to secure regulatory approvals and commercialize its therapies.

Alaunos Therapeutics, Inc. (TCRT) Mission Statement

Alaunos Therapeutics, Inc. is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With a robust and innovative discovery engine, Alaunos strikes cancer at its core by engineering cell therapies that target neoantigens arising from genomic mutations.

The company is focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR.

Here's a breakdown of the key components of Alaunos Therapeutics' mission:

• Focus on TCR-T Cell Therapy: Alaunos Therapeutics is dedicated to advancing cancer treatment through T-cell receptor (TCR) therapies.
• Targeting Solid Tumors: The company directs its efforts toward developing treatments for solid tumors, which represent a significant challenge in oncology.
• Innovative Technology: Alaunos employs its proprietary Sleeping Beauty platform for gene transfer, alongside its TCR library, to target tumor-specific mutations.

The name Alaunos originates from the Celtic mythological god of healing, reflecting the Company's commitment to developing therapies for cancer patients.

Alaunos's focus on precision medicine is evident through its development of personalized TCR-T cell therapies. This approach leverages the Sleeping Beauty technology to potentially increase the addressable population for TCR-T therapies.

The company's activities include the research and development of non-viral T-cell therapy platforms, specifically targeting neoantigens through TCR-T cell therapies. Alaunos Therapeutics' products include the Sleeping Beauty transposon/transposase system and the hunTR platform, that are used to genetically modify T-cell receptors to target cancer-specific mutations. The company's products are primarily utilized by healthcare providers and researchers in the oncology sector to treat solid tumors.

In 2024, Alaunos Therapeutics reported a revenue of $10,000 and a net loss of $4.68 million, or $2.92 per share.

As of April 10, 2025, Alaunos Therapeutics's stock price is $2.81. Its current market cap is $4.58M with 1.6M shares.

For more insights into Alaunos Therapeutics, explore this resource: Alaunos Therapeutics, Inc. (TCRT): History, Ownership, Mission, How It Works & Makes Money

Alaunos Therapeutics, Inc. (TCRT) Vision Statement

To fully understand Alaunos Therapeutics, Inc. (TCRT), it's essential to examine its mission, vision, and core values. These elements provide a clear picture of the company's goals, aspirations, and the principles that guide its operations. Understanding these statements helps stakeholders gauge the company's direction and commitment.

Mission Statement

Alaunos Therapeutics' mission is centered on developing transformative T-cell receptor (TCR) therapies to eliminate solid tumors. This mission reflects a commitment to innovation in cancer treatment and a focus on addressing unmet medical needs. The company aims to harness the power of the immune system to target and destroy cancer cells, providing potentially curative options for patients with solid tumors. As of the fiscal year 2024, Alaunos Therapeutics is focused on advancing its TCR-T cell therapy pipeline, with a particular emphasis on addressing significant challenges in the treatment of solid tumors.

Vision Statement

The vision of Alaunos Therapeutics is to revolutionize the treatment of solid tumors through innovative TCR-T cell therapies. The company strives to become a leader in the field of cancer immunotherapy by developing and delivering groundbreaking treatments that improve patient outcomes and transform the lives of individuals affected by cancer. As of 2024, this vision is underpinned by ongoing clinical trials and research programs aimed at validating the efficacy and safety of its TCR-T cell therapies.

Alaunos Therapeutics is dedicated to revolutionizing cancer treatment. Their vision extends beyond immediate financial gains, focusing on making a lasting impact on global health. Here’s how they break it down:

• Innovation in TCR-T Cell Therapies: Alaunos seeks to pioneer new methods in cancer treatment. This involves ongoing research and development to refine their TCR-T cell therapies, ensuring they remain at the cutting edge of medical science.
• Transforming Patient Outcomes: The ultimate goal is to significantly improve the lives of cancer patients. This includes not only extending life expectancy but also enhancing the quality of life during and after treatment.
• Leadership in Cancer Immunotherapy: Alaunos aims to be recognized as a key player in the immunotherapy field. This involves setting new standards for treatment efficacy and patient care.

This vision is ambitious, requiring continuous innovation and adaptation to the evolving landscape of cancer treatment.

Core Values

Alaunos Therapeutics' core values guide its actions and shape its culture. These values include:

• Innovation: A commitment to pushing the boundaries of science and technology to develop novel therapies.
• Patient-Centricity: A focus on the needs and well-being of patients, ensuring that all efforts are directed towards improving their lives.
• Integrity: Adherence to the highest ethical standards in all aspects of the business, including research, development, and patient care.
• Collaboration: Fostering a collaborative environment that encourages teamwork, knowledge sharing, and mutual respect.

These values drive the company's commitment to making a meaningful difference in the fight against cancer. These principles ensure that the company operates responsibly and ethically, building trust with patients, partners, and stakeholders.

To gain a deeper understanding of investor sentiment and activity surrounding Alaunos Therapeutics, explore this insightful resource: Exploring Alaunos Therapeutics, Inc. (TCRT) Investor Profile: Who’s Buying and Why?

Alaunos Therapeutics, Inc. (TCRT) Core Values of

While direct information on the core values, mission, and vision of Alaunos Therapeutics, Inc. is limited, we can infer their guiding principles from their actions, goals, and public statements, particularly as they relate to their work in the field of T-cell receptor (TCR) therapies for cancer. Understanding these inferred values provides insight into the company's culture and strategic direction.

Based on available information, potential core values might include:

• Innovation: Alaunos focuses on developing novel T-cell receptor (TCR) therapies.
• Patient-centricity: A commitment to developing effective cancer treatments.
• Scientific Rigor: Dedication to high-quality research and development.

Innovation:

Innovation appears to be a central value for Alaunos Therapeutics, given their focus on pioneering new approaches to cancer treatment. Their work revolves around developing novel T-cell receptor (TCR) therapies, which represents a cutting-edge area in cancer immunotherapy. This commitment to innovation is evident in their research and development efforts, where they strive to create new and more effective treatments for patients with solid tumors. For example, Alaunos is working on therapies targeting specific mutations and tumor types, showcasing their dedication to pushing the boundaries of cancer treatment. This innovative spirit is crucial in a field that demands constant evolution to overcome the challenges posed by cancer.

Patient-Centricity:

Alaunos Therapeutics' commitment to patient-centricity is reflected in its mission to develop effective cancer treatments. This value places the well-being of patients at the forefront of their efforts, guiding their research and development activities. The company's focus on developing personalized T-cell receptor (TCR) therapies demonstrates a deep understanding of the unique needs of each patient. By tailoring treatments to specific tumor types and genetic profiles, Alaunos aims to improve outcomes and enhance the quality of life for individuals battling cancer. This patient-centric approach is essential in the healthcare industry, where the ultimate goal is to provide the best possible care and support for those in need.

Scientific Rigor:

Scientific rigor is a fundamental value for Alaunos Therapeutics, underpinning their commitment to high-quality research and development. This dedication is evident in their meticulous approach to developing T-cell receptor (TCR) therapies, ensuring that each treatment is thoroughly tested and validated. Alaunos adheres to strict scientific standards in their preclinical and clinical studies, carefully evaluating the safety and efficacy of their therapies. By prioritizing scientific rigor, the company aims to build confidence in their treatments and ensure that they meet the highest standards of quality and reliability. This commitment to excellence is essential in the field of cancer immunotherapy, where precision and accuracy are paramount.

To gain more insights into the investors profile, please visit: Exploring Alaunos Therapeutics, Inc. (TCRT) Investor Profile: Who’s Buying and Why?